T cells responses against the EBV antigens have been elicited in Burkitt lymphoma (BL), nasopharyngeal cancer (NPC) and Hodgkin disease (HD), but have been insufficient to eradicate tumor cells. Current approach mainly focuses on CD8+T effector cells appears inadequate for the generation of optimal antitumor immunity. Increasing evidence from both human and animal studies indicates that CD4+ T (helper) cells play a central role in initiating and maintaining the host immune responses against cancer. While a few MHC class II-restricted EBNA1 peptides have been reported, the role of such peptides and their cognate CD4+ T cells in antitumor immunity is unknown. Thus, it is critical to develop a preclinical tumor model for developing novel strategies to enhance antitumor immune responses. We hypothesize that MHC class II-restricted peptides from EBNA1 as well as from previously unrecognized tumor antigens, can be identified in EBV-positive tumor cells and used to activate CD4+ T cells, leading to more potent antitumor immunity. To test this hypothesis, we propose to identify and evaluate MHC class II-restricted viral/tumor peptides from EVB-associated tumors. With these T helper epitopes in hand, their optimal use will require greater knowledge of effective vaccine strategies and the antitumor role of antigen-specific CD4+ T cells. A lack of an animal model for EBV-associated tumors poses a major obstacle for obtaining such knowledge and understanding of development of effective vaccines against EVB-associated cancer. Thus, we further propose to establish a murine BL model characterized by expression of EBNA1, and exploit it to define the role of CD4+ T cells in cellular immune responses against BL tumors by a novel antigen delivery system developed in the Pl's laboratory. Finally, we plan to elucidate the mechanism of CD4+ T-cell-mediated antitumor immunity, to determine whether CD4+ T cells exert antitumor effects by direct or indirect tumor killing mechanisms, and/or through the role of cytokines secreted by CD4+ T cells. It is anticipated that these studies will advance the field of immunotherapy of cancer and provide a foundation for the development of novel approaches for effective cancer vaccines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA101795-04
Application #
7231379
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Daschner, Phillip J
Project Start
2004-07-01
Project End
2009-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
4
Fiscal Year
2007
Total Cost
$263,284
Indirect Cost
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Sheng, Si Yuan; Gu, Yong; Lu, Chuan Gang et al. (2017) The distribution and function of human memory T cell subsets in lung cancer. Immunol Res 65:639-650
Cai, Baowei; Wu, Jian; Yu, Xiao et al. (2017) FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions. MBio 8:
Ning, Bo; Zhao, Wei; Qian, Chen et al. (2017) USP26 functions as a negative regulator of cellular reprogramming by stabilising PRC1 complex components. Nat Commun 8:349
Zhang, Jindong; Zhang, Chuanxia; Cui, Jun et al. (2017) TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination. Cell Death Dis 8:e2831
Wang, Rong-Fu; Wang, Helen Y (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27:11-37
Jin, Shouheng; Tian, Shuo; Chen, Yamei et al. (2016) USP19 modulates autophagy and antiviral immune responses by deubiquitinating Beclin-1. EMBO J 35:866-80
Qin, Yunfei; Liu, Qingxiang; Tian, Shuo et al. (2016) TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3? to TBK1. Cell Res 26:613-28
Ning, Bo; Li, Wenyuan; Zhao, Wei et al. (2016) Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) 48:97-109
Yang, Zhifen; Xian, Huifang; Hu, Jiajia et al. (2015) USP18 negatively regulates NF-?B signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. Sci Rep 5:12738
Burchfield, Jana S; Li, Qingtian; Wang, Helen Y et al. (2015) JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol 67:148-57

Showing the most recent 10 out of 32 publications